nach oben

Current Hematologic Malignancy Reports

Erschienen in:

01.12.2015 | Myeloproliferative Disorders (C Harrison, Section Editor)

Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations

verfasst von: Xavier Cahu, Stefan N. Constantinescu

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

During the past 10 years, major progress has been accomplished with the discovery of activating mutations that are associated with the vast majority of BCR-ABL negative human myeloproliferative neoplasms (MPNs). The identification in 2005 of JAK2 V617F triggered great interest in the JAK2-STAT5/STAT3 pathway. Discovery in 2006 of mutants of thrombopoietin receptor (TPO-R/MPL) and later on of mutants in negative regulators of JAK-STAT pathway led to the notion that persistent JAK2 activation is a hallmark of MPNs. In 2013, mutations in the gene coding for the chaperone calreticulin were reported in 20–30 % of essential thrombocythemia and primary myelofibrosis patients. Here, we will address the question: what do we know about calreticulin that could help us understand its role in MPNs? In addition to oncogenic driver mutations, certain MPNs also exhibit epigenetic mutations. Targeting of both oncogenic drivers and epigenetic defects could be required for effective therapy.

Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene. 2013;32(21):2601–13. doi:10.1038/onc.2012.347.CrossRefPubMed

2.•

Bandaranayake RM, Ungureanu D, Shan Y, Shaw DE, Silvennoinen O, Hubbard SR. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat Struct Mol Biol. 2012;19(8):754–9. doi:10.1038/nsmb.2348. This study describes JAK2 V617F pseudokinase domain.PubMedCentralCrossRefPubMed

3.••

Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–90. doi:10.1056/NEJMoa1311347. This study describes CALR mutations in MPN for the first time.CrossRefPubMed

4.••

Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–405. doi:10.1056/NEJMoa1312542. This study describes CALR mutations in MPN for the first time.PubMedCentralCrossRefPubMed

5.•

Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123(22):e123–33. doi:10.1182/blood-2014-02-554634. This study provides a comprehensive genomic and transcriptomic analysis of MPN.PubMedCentralCrossRefPubMed

Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459–68. doi:10.1056/NEJMoa065202.PubMedCentralCrossRefPubMed

James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–8. doi:10.1038/nature03546.CrossRefPubMed

Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–97. doi:10.1016/j.ccr.2005.03.023.CrossRefPubMed

Kralovics R, Teo SS, Buser AS, Brutsche M, Tiedt R, Tichelli A, et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood. 2005;106(10):3374–6. doi:10.1182/blood-2005-05-1889.CrossRefPubMed

10.

Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054–61. doi:10.1016/S0140-6736(05)71142-9.CrossRefPubMed

11.

Dusa A, Staerk J, Elliott J, Pecquet C, Poirel HA, Johnston JA, et al. Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2. J Biol Chem. 2008;283(19):12941–8. doi:10.1074/jbc.M709302200.CrossRefPubMed

12.

Dusa A, Mouton C, Pecquet C, Herman M, Constantinescu SN. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. PLoS One. 2010;5(6):e11157. doi:10.1371/journal.pone.0011157.PubMedCentralCrossRefPubMed

13.

Silvennoinen O, Hubbard SR. Molecular insights into regulation of JAK2 in myeloproliferative neoplasms. Blood. 2015. doi:10.1182/blood-2015-01-621110.PubMedCentralPubMed

14.

Sangkhae V, Etheridge SL, Kaushansky K, Hitchcock IS. The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm. Blood. 2014;124(26):3956–63. doi:10.1182/blood-2014-07-587238.CrossRefPubMed

15.

Walz C, Ahmed W, Lazarides K, Betancur M, Patel N, Hennighausen L, et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood. 2012;119(15):3550–60. doi:10.1182/blood-2011-12-397554.PubMedCentralCrossRefPubMed

16.

Yan D, Hutchison RE, Mohi G. Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood. 2012;119(15):3539–49. doi:10.1182/blood-2011-03-345215.PubMedCentralCrossRefPubMed

17.

Moucadel V, Constantinescu SN. Differential STAT5 signaling by ligand-dependent and constitutively active cytokine receptors. J Biol Chem. 2005;280(14):13364–73. doi:10.1074/jbc.M407326200.CrossRefPubMed

18.

Girardot M, Pecquet C, Boukour S, Knoops L, Ferrant A, Vainchenker W, et al. miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. Blood. 2010;116(3):437–45. doi:10.1182/blood-2008-06-165985.CrossRefPubMed

19.

Girardot M, Pecquet C, Chachoua I, Van Hees J, Guibert S, Ferrant A, et al. Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation. Oncogene. 2014. doi:10.1038/onc.2014.60.PubMed

20.

Duek A, Lundberg P, Shimizu T, Grisouard J, Karow A, Kubovcakova L, et al. Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs. Blood. 2014;123(25):3943–50. doi:10.1182/blood-2013-07-514208.CrossRefPubMed

21.

Grisouard J, Shimizu T, Duek A, Kubovcakova L, Hao-Shen H, Dirnhofer S, et al. Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN. Blood. 2015. doi:10.1182/blood-2014-08-594572.PubMed

22.

Chen E, Ahn JS, Massie CE, Clynes D, Godfrey AL, Li J, et al. JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response. Proc Natl Acad Sci U S A. 2014;111(42):15190–5. doi:10.1073/pnas.1401873111.PubMedCentralCrossRefPubMed

23.

Lundberg P, Takizawa H, Kubovcakova L, Guo G, Hao-Shen H, Dirnhofer S, et al. Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. J Exp Med. 2014;211(11):2213–30. doi:10.1084/jem.20131371.PubMedCentralCrossRefPubMed

24.

Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010;17(6):584–96. doi:10.1016/j.ccr.2010.05.015.PubMedCentralCrossRefPubMed

25.

Kubovcakova L, Lundberg P, Grisouard J, Hao-Shen H, Romanet V, Andraos R, et al. Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood. 2013;121(7):1188–99. doi:10.1182/blood-2012-03-415646.CrossRefPubMed

26.

Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270. doi:10.1371/journal.pmed.0030270.PubMedCentralCrossRefPubMed

27.

Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472–6. doi:10.1182/blood-2006-04-018879.CrossRefPubMed

28.

Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, Constantinescu SN. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood. 2006;107(5):1864–71. doi:10.1182/blood-2005-06-2600.PubMedCentralCrossRefPubMed

29.

Defour JP, Itaya M, Gryshkova V, Brett IC, Pecquet C, Sato T, et al. Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation. Proc Natl Acad Sci U S A. 2013;110(7):2540–5. doi:10.1073/pnas.1211560110.PubMedCentralCrossRefPubMed

30.

Pecquet C, Staerk J, Chaligne R, Goss V, Lee KA, Zhang X, et al. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood. 2010;115(5):1037–48. doi:10.1182/blood-2008-10-183558.CrossRefPubMed

31.

Dudek-Peric AM, Ferreira GB, Muchowicz A, Wouters J, Prada N, Martin S, et al. Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. Cancer Res. 2015;75(8):1603–14. doi:10.1158/0008-5472.CAN-14-2089.CrossRefPubMed

32.

Wang WA, Groenendyk J, Michalak M. Calreticulin signaling in health and disease. Int J Biochem Cell Biol. 2012;44(6):842–6. doi:10.1016/j.biocel.2012.02.009.CrossRefPubMed

33.

Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005;123(2):321–34. doi:10.1016/j.cell.2005.08.032.CrossRefPubMed

34.

Kepp O, Menger L, Vacchelli E, Locher C, Adjemian S, Yamazaki T, et al. Crosstalk between ER stress and immunogenic cell death. Cytokine Growth Factor Rev. 2013;24(4):311–8. doi:10.1016/j.cytogfr.2013.05.001.CrossRefPubMed

35.

Tannous A, Pisoni GB, Hebert DN, Molinari M. N-linked sugar-regulated protein folding and quality control in the ER. Semin Cell Dev Biol. 2014. doi:10.1016/j.semcdb.2014.12.001.PubMedCentralPubMed

36.

Hebert DN, Foellmer B, Helenius A. Glucose trimming and reglucosylation determine glycoprotein association with calnexin in the endoplasmic reticulum. Cell. 1995;81(3):425–33.CrossRefPubMed

37.

Wijeyesakere SJ, Rizvi SM, Raghavan M. Glycan-dependent and -independent interactions contribute to cellular substrate recruitment by calreticulin. J Biol Chem. 2013;288(49):35104–16. doi:10.1074/jbc.M113.507921.PubMedCentralCrossRefPubMed

38.

Kozlov G, Pocanschi CL, Rosenauer A, Bastos-Aristizabal S, Gorelik A, Williams DB, et al. Structural basis of carbohydrate recognition by calreticulin. J Biol Chem. 2010;285(49):38612–20. doi:10.1074/jbc.M110.168294.PubMedCentralCrossRefPubMed

39.

Chouquet A, Paidassi H, Ling WL, Frachet P, Houen G, Arlaud GJ, et al. X-ray structure of the human calreticulin globular domain reveals a peptide-binding area and suggests a multi-molecular mechanism. PLoS One. 2011;6(3):e17886. doi:10.1371/journal.pone.0017886.PubMedCentralCrossRefPubMed

40.

Marty C, Harini N, Pecquet C, Chachoua I, Gryshkova V, Villeval JL, et al. (2014) Calr Mutants Retroviral Mouse Models Lead to a Myeloproliferative Neoplasm Mimicking an Essential Thrombocythemia Progressing to a Myelofibrosis Blood (ASH Annual Meeting Abstracts) 124 (21):Abstract 157

41.

Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544–51. doi:10.1182/blood-2013-11-539098.PubMedCentralCrossRefPubMed

42.

Broseus J, Park JH, Carillo S, Hermouet S, Girodon F. Presence of calreticulin mutations in JAK2-negative polycythemia vera. Blood. 2014;124(26):3964–6. doi:10.1182/blood-2014-06-583161.CrossRefPubMed

43.

Cabagnols X, Cayuela JM, Vainchenker W. A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm. N Engl J Med. 2015;372(7):688–90. doi:10.1056/NEJMc1413718.CrossRefPubMed

44.

Passamonti F, Caramazza D, Maffioli M. JAK inhibitor in CALR-mutant myelofibrosis. N Engl J Med. 2014;370(12):1168–9. doi:10.1056/NEJMc1400499#SA1.CrossRefPubMed

45.

Cassinat B, Verger E, Kiladjian JJ. Interferon alfa therapy in CALR-mutated essential thrombocythemia. N Engl J Med. 2014;371(2):188–9. doi:10.1056/NEJMc1401255.CrossRefPubMed

46.

Kollmann K, Nangalia J, Warsch W, Quentmeier H, Bench A, Boyd E, et al. MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling. Leukemia. 2014. doi:10.1038/leu.2014.285.

47.

Yoshida H, Kondo M, Ichihashi T, Hashimoto N, Inazawa J, Ohno R, et al. A novel myeloid cell line, Marimo, derived from therapy-related acute myeloid leukemia during treatment of essential thrombocythemia: consistent chromosomal abnormalities and temporary C-MYC gene amplification. Cancer Genet Cytogenet. 1998;100(1):21–4.CrossRefPubMed

48.

Cabagnols X, Defour JP, Ugo V, Ianotto JC, Mossuz P, Mondet J, et al. (2014) Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia Sep 19. doi: 10.1038/leu.2014.270

49.

Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martinez-Trillos A, Casetti I, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124(7):1062–9. doi:10.1182/blood-2014-05-578435.PubMedCentralCrossRefPubMed

50.

Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507–13. doi:10.1182/blood-2014-05-579136.PubMedCentralCrossRefPubMed

51.

Tefferi A, Lasho TL, Tischer A, Wassie EA, Finke CM, Belachew AA, et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood. 2014;124(15):2465–6. doi:10.1182/blood-2014-07-588426.PubMedCentralCrossRefPubMed

52.•

Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220–8. doi:10.1182/blood-2013-11-537167. This study provides a comprehensive analysis of somatic mutations in MPN.CrossRefPubMed

53.

Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci U S A. 2014;111(50):E5401–10. doi:10.1073/pnas.1407792111.PubMedCentralCrossRefPubMed

54.

Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289–301. doi:10.1056/NEJMoa0810069.CrossRefPubMed

55.

Delatte B, Deplus R, Fuks F. Playing TETris with DNA modifications. EMBO J. 2014;33(11):1198–211. doi:10.15252/embj.201488290.PubMedCentralPubMed

56.

Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372(7):601–12. doi:10.1056/NEJMoa1412098.PubMedCentralCrossRefPubMed

57.

Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20(1):11–24. doi:10.1016/j.ccr.2011.06.001.PubMedCentralCrossRefPubMed

58.

Kameda T, Shide K, Yamaji T, Kamiunten A, Sekine M, Taniguchi Y, et al. Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator. Blood. 2015;125(2):304–15. doi:10.1182/blood-2014-04-555508.CrossRefPubMed

59.

Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009;23(5):905–11. doi:10.1038/leu.2009.47.PubMedCentralCrossRefPubMed

60.

Abdel-Wahab O, Pardanani A, Rampal R, Lasho TL, Levine RL, Tefferi A. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia. 2011;25(7):1219–20. doi:10.1038/leu.2011.82.PubMedCentralCrossRefPubMed

61.

Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42(8):722–6. doi:10.1038/ng.621.CrossRefPubMed

62.

Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adelaide J, Rey J, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009;23(11):2183–6. doi:10.1038/leu.2009.141.CrossRefPubMed

63.

Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med. 2010;362(4):369–70. doi:10.1056/NEJMc0910063.CrossRefPubMed

64.

Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brustle A, et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature. 2012;488(7413):656–9. doi:10.1038/nature11323.PubMedCentralCrossRefPubMed

65.

Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. p53 lesions in leukemic transformation. N Engl J Med. 2011;364(5):488–90. doi:10.1056/NEJMc1012718.CrossRefPubMed

66.

Mascarenhas J, Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res. 2012;18(11):3008–14. doi:10.1158/1078-0432.CCR-11-3145.CrossRefPubMed

67.••

Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–98. doi:10.1056/NEJMoa1110556.This study is one of the two COMFORT trials reporting the efficacy of ruxolitinib.

68.••

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807. doi:10.1056/NEJMoa1110557. This study is one of the two COMFORT trials reporting the efficacy of ruxolitinib.

69.••

Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426–35. doi:10.1056/NEJMoa1409002. This study is the RESPONSE trial.

70.

Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012;489(7414):155–9. doi:10.1038/nature11303.PubMedCentralCrossRefPubMed

71.

Manshouri T, Estrov Z, Quintas-Cardama A, Burger J, Zhang Y, Livun A, et al. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res. 2011;71(11):3831–40. doi:10.1158/0008-5472.CAN-10-4002.PubMedCentralCrossRefPubMed

72.

Choong ML, Pecquet C, Pendharkar V, Diaconu CC, Yong JW, Tai SJ, et al. Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. J Cell Mol Med. 2013;17(11):1397–409. doi:10.1111/jcmm.12156.PubMedCentralCrossRefPubMed

73.

Bartalucci N, Tozzi L, Bogani C, Martinelli S, Rotunno G, Villeval JL, et al. Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. J Cell Mol Med. 2013;17(11):1385–96. doi:10.1111/jcmm.12162.PubMedCentralCrossRefPubMed

74.

Bhagwat N, Koppikar P, Keller M, Marubayashi S, Shank K, Rampal R, et al. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood. 2014;123(13):2075–83. doi:10.1182/blood-2014-01-547760.PubMedCentralCrossRefPubMed

75.

Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol. 2011;86(8):668–76. doi:10.1002/ajh.22063.CrossRefPubMed

Titel: Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations
verfasst von: Xavier Cahu
Stefan N. Constantinescu
Publikationsdatum: 01.12.2015
Verlag: Springer US
Erschienen in: Current Hematologic Malignancy Reports / Ausgabe 4/2015
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-015-0278-x

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

Social Media and the Practicing Hematologist: Twitter 101 for the Busy Healthcare Provider

Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis

Immunological Consequences of JAK Inhibition: Friend or Foe?

What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies

Current Challenges in Stem Cell Transplantation in Myelofibrosis

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie